In conclusion, this study demonstrated the dominant activation of the adaptive IRE1α pathway in patients with NDMM and the anti-myeloma effects of KIRA8 and nilotinib with the reciprocal induction of CHOP. The gene discussed is ERN1; the disease is plasma cell myeloma.